Compare RNST & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | VERA |
|---|---|---|
| Founded | 1904 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | RNST | VERA |
|---|---|---|
| Price | $36.48 | $54.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $43.17 | ★ $76.60 |
| AVG Volume (30 Days) | 590.2K | ★ 2.0M |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $775,309,000.00 | N/A |
| Revenue This Year | $43.37 | N/A |
| Revenue Next Year | $13.13 | N/A |
| P/E Ratio | $19.87 | ★ N/A |
| Revenue Growth | ★ 13.04 | N/A |
| 52 Week Low | $26.97 | $18.53 |
| 52 Week High | $40.40 | $54.57 |
| Indicator | RNST | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 80.97 |
| Support Level | $36.84 | $47.22 |
| Resistance Level | $37.76 | $51.19 |
| Average True Range (ATR) | 0.70 | 3.30 |
| MACD | 0.01 | 0.62 |
| Stochastic Oscillator | 40.37 | 95.60 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.